Dublin-headquartered med tech company Mainstay Medical has filed two patents that will be central to new products that will help tackle debilitating back pain.
Mainstay – which is listed on the Dublin and Paris stock exchanges – is a medtech player that is focused on the commercialisation of novel neurostimulation therapies for people suffering from chronic lower back pain (CLBP).
Mainstay moved its head office and executive leadership team from Minnesota to Dublin in 2012.
The company’s ReActiv8 unique approach is to use electrical stimulation to elicit repetitive contractions of the key stabilising muscles of the lumbar spine to reactivate the body’s control over these muscles, allowing recovery from CLBP.
“Our approach to the treatment of CLBP in this challenging population is unique,” said CEO Peter Crosby.
“We are proud of our intellectual property portfolio, and look forward to the continued development of the portfolio in the coming years.”
Clinical trials with ReActiv8 are ongoing in Europe and Australia, and the company recently announced FDA approval to start a clinical trial of ReActiv8 in the US under an Investigational Device Exception (IDE).
The two new patents issued to Mainstay are:
- U.S. Patent No. 9,072,897 entitled “Systems and Methods for Restoring Muscle Function to the Lumbar Spine.”
- U.S. Patent No. 9,079,019 entitled “Apparatus and Methods for Anchoring Electrode Leads for Use with Implantable Neuromuscular Electrical Stimulator.”